It is simple enough to enumerate the shortcomings of existing pharmacotherapies for depression: the desire for drugs with faster onsets, higher remission rates, fewer side effects, robust anti-suic...
No takes yet. Share an insight, caveat, or question.
Goldberg et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: